\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

\n
Value of calprotectin analysis<\/h1>Featured Articles<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nby Dr Ruth Ayling<\/em><\/p>\n
Calprotectin is a protein derived from neutrophils and its presence in feces can be used as a surrogate marker of gastrointestinal inflammation. Measurement is useful to differentiate inflammatory bowel disorder (IBD) from functional bowel disease, which has similar clinical features but different etiology, and to manage patients with established IBD.<\/strong><\/p>\n
<\/p>\n
Calprotectin and its use in gastrointestinal disease<\/h3>\nCalprotectin is a 36-kDa member of the S100 family of calcium binding proteins. It is a heterodimer of the proteins S100A8 and S100A9 each of which can bind two Ca2+ ions and other divalent metal ions, for example zinc (Fig. 1). Calprotectin has a direct antimicrobial effect related to its ability to chelate metal ions and is involved in the innate immune response. Calprotectin is derived predominantly from neutrophils and accounts for about 60% of their cytosolic protein. It is found in various body fluids in proportion to the severity of any existing inflammation. The concentration of calprotectin in the feces of healthy individuals is about six times that of normal plasma, which led to the concept of its measurement in feces as a marker of gastrointestinal inflammation.<\/p>\n
Gastrointestinal disorders are common and make up a sizeable proportion of the workload in primary care. Symptoms may be the result of disorders which have a demonstrable pathology or arise from functional disorders, in which gastrointestinal symptoms occur but no cause for them can be found. The inflammatory bowel disorders (IBDs) ulcerative colitis (UC) and Crohn\u2019s disease (CD) are two organic bowel diseases for which calprotectin measurement has particular relevance. IBDs are believed to occur in a genetically susceptible host as a result of dysregulation of the immune response to commensal microbiota, but their pathophysiology is not completely determined. Both disorders are most common in young patients, peak incidence occurring between 15 and 30 years of age, with a peak prevalence of up to 0.5% in Western countries. CD can affect any part of the gastrointestinal tract and the characteristic histological appearance is of granulomatous inflammation which is transmural in extent. In UC, disease activity is limited to the colon and the inflammation is confirmed to the mucosal layer. The most common functional bowel disorder is irritable bowel syndrome, which has been estimated to have a worldwide prevalence of 11.2%.<\/p>\n<\/div><\/section>
\n
by Dr Ruth Ayling<\/em><\/p>\n
Calprotectin is a protein derived from neutrophils and its presence in feces can be used as a surrogate marker of gastrointestinal inflammation. Measurement is useful to differentiate inflammatory bowel disorder (IBD) from functional bowel disease, which has similar clinical features but different etiology, and to manage patients with established IBD.<\/strong><\/p>\n
<\/p>\n
Calprotectin and its use in gastrointestinal disease<\/h3>\nCalprotectin is a 36-kDa member of the S100 family of calcium binding proteins. It is a heterodimer of the proteins S100A8 and S100A9 each of which can bind two Ca2+ ions and other divalent metal ions, for example zinc (Fig. 1). Calprotectin has a direct antimicrobial effect related to its ability to chelate metal ions and is involved in the innate immune response. Calprotectin is derived predominantly from neutrophils and accounts for about 60% of their cytosolic protein. It is found in various body fluids in proportion to the severity of any existing inflammation. The concentration of calprotectin in the feces of healthy individuals is about six times that of normal plasma, which led to the concept of its measurement in feces as a marker of gastrointestinal inflammation.<\/p>\n
Gastrointestinal disorders are common and make up a sizeable proportion of the workload in primary care. Symptoms may be the result of disorders which have a demonstrable pathology or arise from functional disorders, in which gastrointestinal symptoms occur but no cause for them can be found. The inflammatory bowel disorders (IBDs) ulcerative colitis (UC) and Crohn\u2019s disease (CD) are two organic bowel diseases for which calprotectin measurement has particular relevance. IBDs are believed to occur in a genetically susceptible host as a result of dysregulation of the immune response to commensal microbiota, but their pathophysiology is not completely determined. Both disorders are most common in young patients, peak incidence occurring between 15 and 30 years of age, with a peak prevalence of up to 0.5% in Western countries. CD can affect any part of the gastrointestinal tract and the characteristic histological appearance is of granulomatous inflammation which is transmural in extent. In UC, disease activity is limited to the colon and the inflammation is confirmed to the mucosal layer. The most common functional bowel disorder is irritable bowel syndrome, which has been estimated to have a worldwide prevalence of 11.2%.<\/p>\n<\/div><\/section>
\n
\n